Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock Position Lifted by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 21.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,107 shares of the medical instruments supplier’s stock after buying an additional 6,292 shares during the quarter. Principal Financial Group Inc. owned approximately 0.65% of Mesa Laboratories worth $4,559,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Amalgamated Bank raised its holdings in shares of Mesa Laboratories by 6.5% during the third quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock worth $206,000 after acquiring an additional 97 shares in the last quarter. FMR LLC raised its stake in shares of Mesa Laboratories by 34.1% during the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 100 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Mesa Laboratories by 1.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 11,461 shares of the medical instruments supplier’s stock valued at $1,488,000 after buying an additional 200 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Mesa Laboratories in the 2nd quarter valued at approximately $26,000. Finally, Quantbot Technologies LP acquired a new position in Mesa Laboratories in the third quarter worth approximately $70,000. Institutional investors and hedge funds own 90.60% of the company’s stock.

Insider Buying and Selling

In other Mesa Laboratories news, CEO Gary M. Owens sold 2,518 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the transaction, the chief executive officer now owns 45,888 shares of the company’s stock, valued at $5,213,794.56. The trade was a 5.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.40% of the stock is owned by insiders.

Mesa Laboratories Stock Up 0.1 %

Shares of Mesa Laboratories stock opened at $131.97 on Friday. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $141.17. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average price of $121.04 and a two-hundred day moving average price of $118.20. The stock has a market capitalization of $716.73 million, a P/E ratio of -2.90 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several research firms have commented on MLAB. StockNews.com downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Evercore ISI upped their price objective on shares of Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.